ASX-listed healthcare companies have long had an outsized impact on global markets.
Think CSL Ltd (ASX: CSL), ResMed Inc (ASX: RMD), and Cochlear Ltd (ASX: COH).
For shareholders who got in it early with those companies, the rewards have been significant.
So, when an ASX healthcare share gains 250% in a year, it could be worth examining closely.
Orthocell Ltd (ASX: OCC), a Perth-based biotech company, develops regenerative medicine to treat musculoskeletal disorders.
And its flagship nerve repair product, Remplir, is gaining traction in Australia and overseas.
The company this week announced it had achieved record revenue of $2.73 million for the June quarter.
That represents an increase of 22.8% on the previous quarter and the fifth consecutive quarter of record revenue for the company.
Orthocell CEO Paul Anderson said his company is in the early stages of tapping a global addressable nerve repair market worth US$3.5 billion.
This outstanding result is driven by growing demand from surgeons in our existing markets and lays a solid foundation for our US expansion which we expect to ramp up in the first half of FY26.
We're seeing our commercialisation strategy in Australia starting to bear fruit and we are confident this will be replicated on a much larger scale in the US.
Orthocell's Remplir product is a collagen wrap used in nerve repair surgery to repair and regenerate damaged nerves.
Recent studies confirm its superiority over the traditional needle and thread method for nerve repair, according to Orthocell.
Image source: Getty Images
On track for success
And the company has stated that its US Remplir commercialisation program remains "on track" following the first surgical use of Remplir in the US.
Remplir was granted FDA approval earlier this year.
Anderson said Orthocell is expanding customer networks across 25 US states to accelerate revenue growth in the US.
With our highly experienced US distributors appointed and our first surgical use completed after achieving FDA clearance, we are well-positioned to accelerate growth in the US$1.6 billion nerve repair market over the coming months.
Orthocell ended the quarter with $28.5 million in cash in the bank and no debt.
As such, the company looks to be well funded to continue to grow in new and existing markets.
The Orthocell share price has continued to climb this week, gaining about 10%. The company's shares are currently trading at around $1.29 each.
